MHRA enforcement and unlicensed medicines
The MHRA is the lead UK regulator for medicines, devices, and blood products. For peptides, MHRA enforcement is the backbone of the regulatory framework that sits behind everything else on this site. This page sets out what enforcement looks like in practice.
The MHRA's statutory role
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care. Its statutory remit covers medicines, medical devices, and blood components for transfusion. For peptides specifically, MHRA is the lead enforcer of the Human Medicines Regulations 2012 (HMR 2012) and operates the Yellow Card adverse-event reporting scheme.
The key offences under HMR 2012
Enforcement against unlicensed-peptide supply usually rests on one or more of the following provisions in HMR 2012:
- Regulation 46 — placing on the market without a marketing authorisation. Supplying a medicinal product without a UK marketing authorisation (or applicable exemption) is an offence.
- Part 12 — advertising offences. Advertising a POM to the general public, or advertising any medicinal product with false or misleading claims, is prohibited.
- Part 14 — supply offences. Supplying a POM without a prescription, or operating as a pharmacy without GPhC registration, attracts criminal liability.
- Regulation 23 (manufacture). Manufacturing medicines for human use without a manufacturer’s licence is an offence.
Maximum penalties under HMR 2012 include unlimited fines and up to two years’ imprisonment for the most serious supply offences.
The Criminal Enforcement Unit
The MHRA Criminal Enforcement Unit (CEU) investigates serious medicines offences and works alongside the National Crime Agency, UK Border Force, trading standards, and individual police forces. Operations regularly target:
- Counterfeit GLP-1 pens reaching UK patients via online routes.
- Bulk unlicensed-peptide importers and resellers.
- Online “clinics” supplying POMs without proper prescriber involvement.
- Illegal anabolic-steroid and PIED supply chains (peptides often appear in the same investigations).
The CEU publishes occasional case summaries; many cases never appear in public reporting because investigations remain open or end with civil action rather than prosecution.
How a report becomes an enforcement action
- Report received — via the GOV.UK reporting form, from a healthcare professional, from another regulator (ASA, GPhC, Border Force), or from media coverage.
- Triage — MHRA assesses whether the matter is in scope, the safety risk, and the evidence available.
- Initial action — common early steps include website takedown requests, test purchases, intelligence-sharing with other agencies, and asking platforms (search engines, ad networks, payment processors) to remove the offending content.
- Investigation — for cases that proceed, evidence-gathering can include premises searches, seizures, and financial investigations.
- Outcome — disposal can be educational warning, civil enforcement, a compound penalty, or referral to the CPS for prosecution.
What MHRA enforcement is not
- Not a complaints court. MHRA does not adjudicate consumer-vs-clinic disputes about refunds or service quality. That is a civil matter (small claims, trading standards).
- Not the ASA. Misleading peptide advertising is primarily an ASA matter under the CAP code. MHRA gets involved when the advertising crosses into unlicensed-medicines territory.
- Not a substitute for professional regulators. Clinician misconduct goes to the GMC / NMC / GPhC, not MHRA. Clinic premises issues go to CQC / HIS / HIW / RQIA.
- Not an end-user enforcement priority. MHRA generally targets suppliers and facilitators, not consumers. Customs, by contrast, will seize unlicensed-medicine personal imports.
Reporting a peptide seller, clinic, or advert
Use the GOV.UK report form. Include:
- URL(s) of the seller / clinic / advert.
- Screenshots of the claims (including pricing and product naming).
- Any correspondence with the seller.
- Where you encountered it (search result, social media, email).
- Whether harm has occurred.
For clearly fraudulent supply — counterfeit pens, take-the-money sellers — also report to Action Fraud. For adverse events, use Yellow Card (also covers fake medicines that caused harm).
Sources & further reading
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- Report a problem with a medicine or medical device — gov.uk
- MHRA Drug Safety Update — gov.uk
- Yellow Card — yellowcard.mhra.gov.uk
- Action Fraud — actionfraud.police.uk
Frequently asked questions
- What can the MHRA actually do about unlicensed peptides?
- Investigate complaints, seize goods, take websites down, refer for criminal prosecution, and bring civil enforcement under the Human Medicines Regulations 2012. The MHRA Criminal Enforcement Unit handles serious cases; trading standards and the police can be involved.
- What are the offences I can be prosecuted for?
- Unlawful supply of a medicinal product, advertising a POM to the public, marketing an unauthorised medicinal product, and aiding or abetting any of the above. Maximum penalties under HMR 2012 include unlimited fines and up to two years' imprisonment for the most serious supply offences.
- Does the MHRA prosecute individual buyers?
- Prosecutions are typically aimed at suppliers, advertisers, and facilitators rather than individual end-users. Buyers can still attract regulatory attention if they on-supply (sell or distribute to others), import in commercial quantities, or operate as part of a supply chain.
- How do I report an unlicensed peptide seller, clinic, or advert?
- Use the GOV.UK ‘Report a problem with a medicine or medical device’ form. Include the URL, screenshots, and any pricing or correspondence. For clearly fraudulent supply (counterfeit pens, payment-and-disappear sellers) also report to Action Fraud.
- How long does enforcement take?
- Public timelines aren't published. Pattern reports from MHRA suggest website takedowns and seizures can happen relatively quickly once a case is built; criminal prosecutions take longer. Most enforcement activity is invisible to consumers until the press release.